1
|
Gordon K, Gulidov I, Fatkhudinov T, Koryakin S, Kaprin A. Fast and Furious: Fast Neutron Therapy in Cancer Treatment. Int J Part Ther 2022; 9:59-69. [PMID: 36060415 PMCID: PMC9415749 DOI: 10.14338/ijpt-22-00017] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Accepted: 06/17/2022] [Indexed: 11/21/2022] Open
Abstract
Fast neutron therapy has been used for decades. In conjunction with recent advances in photonic techniques, fast neutrons are no longer of much oncologic interest, which is not unequivocally positive, given their undoubted therapeutic value. This mini-review recalls the history of medical research on fast neutrons, considers their physical and radiobiological properties alongside their benefits for cancer treatment, and discusses their place in modern radiation oncology.
Collapse
Affiliation(s)
- Konstantin Gordon
- 1 Federal State Autonomous Educational Institution of Higher Education “People's Friendship University of Russia,” Medical Institution, Moscow, Russia
- 2 A. Tsyb Medical Radiological Research Center—branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Obninsk, Russia
| | - Igor Gulidov
- 2 A. Tsyb Medical Radiological Research Center—branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Obninsk, Russia
| | - Timur Fatkhudinov
- 1 Federal State Autonomous Educational Institution of Higher Education “People's Friendship University of Russia,” Medical Institution, Moscow, Russia
| | - Sergey Koryakin
- 2 A. Tsyb Medical Radiological Research Center—branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Obninsk, Russia
| | - Andrey Kaprin
- 1 Federal State Autonomous Educational Institution of Higher Education “People's Friendship University of Russia,” Medical Institution, Moscow, Russia
- 2 A. Tsyb Medical Radiological Research Center—branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Obninsk, Russia
| |
Collapse
|
2
|
Viscariello N, Greer MD, Parvathaneni U, Liao JJ, Laramore GE, Stewart RD. Comparisons of 3-Dimensional Conformal and Intensity-Modulated Neutron Therapy for Head and Neck Cancers. Int J Part Ther 2021; 8:51-61. [PMID: 34722811 PMCID: PMC8489487 DOI: 10.14338/ijpt-20-00059.1] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Accepted: 03/03/2021] [Indexed: 11/21/2022] Open
Abstract
PURPOSE Neutron therapy is a high linear energy transfer modality that is useful for the treatment of radioresistant head and neck (H&N) cancers. It has been limited to 3-dimensioanal conformal-based fast-neutron therapy (3DCNT), but recent technical advances have enabled the clinical implementation of intensity-modulated neutron therapy (IMNT). This study evaluated the comparative dosimetry of IMNT and 3DCNT plans for the treatment of H&N cancers. MATERIALS AND METHODS Seven H&N IMNT plans were retrospectively created for patients previously treated with 3DCNT at the University of Washington (Seattle). A custom RayStation model with neutron-specific scattering kernels was used for inverse planning. Organ-at-risk (OAR) objectives from the original 3DCNT plan were initially used and were then systematically reduced to investigate the feasibility of improving a therapeutic ratio, defined as the ratio of the mean tumor to OAR dose. The IMNT and 3DCNT plan quality was evaluated using the therapeutic ratio, isodose contours, and dose volume histograms. RESULTS When compared with the 3DCNT plans, IMNT reduces the OAR dose for the equivalent tumor coverage. Moreover, IMNT is most advantageous for OARs in close spatial proximity to the target. For the 7 patients with H&N cancers examined, the therapeutic ratio for IMNT increased by an average of 56% when compared with the 3DCNT. The maximum OAR dose was reduced by an average of 20.5% and 20.7% for the spinal cord and temporal lobe, respectively. The mean dose to the larynx decreased by an average of 80%. CONCLUSION The IMNT significantly decreases the OAR doses compared with 3DCNT and provides comparable tumor coverage. Improvements in the therapeutic ratio with IMNT are especially significant for dose-limiting OARs near tumor targets. Moreover, IMNT provides superior sparing of healthy tissues and creates significant new opportunities to improve the care of patients with H&N cancers treated with neutron therapy.
Collapse
Affiliation(s)
- Natalie Viscariello
- Department of Radiation Oncology, University of Washington, Seattle, WA, USA
| | - Matthew D. Greer
- Department of Radiation Oncology, University of Washington, Seattle, WA, USA
| | | | - Jay J. Liao
- Department of Radiation Oncology, University of Washington, Seattle, WA, USA
| | - George E. Laramore
- Department of Radiation Oncology, University of Washington, Seattle, WA, USA
| | - Robert D. Stewart
- Department of Radiation Oncology, University of Washington, Seattle, WA, USA
| |
Collapse
|
3
|
Oh JY, Lee YJ, Sai S, Ohno T, Kong CB, Lim SH, Kim EH. The Unfolded Protein Response: Neutron-Induced Therapy Autophagy as a Promising Treatment Option for Osteosarcoma. Int J Mol Sci 2020; 21:ijms21113766. [PMID: 32466612 PMCID: PMC7312646 DOI: 10.3390/ijms21113766] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Revised: 05/20/2020] [Accepted: 05/21/2020] [Indexed: 01/10/2023] Open
Abstract
Radiotherapy using high linear energy transfer (LET) radiation results in effectively killing tumor cells while minimizing dose (biological effective) to normal tissues to block toxicity. It is well known that high LET radiation leads to lower cell survival per absorbed dose than low LET radiation. High-linear energy transfer (LET) neutron treatment induces autophagy in tumor cells, but its precise mechanisms in osteosarcoma are unknown. Here, we investigated this mechanism and the underlying signaling pathways. Autophagy induction was examined in gamma-ray-treated KHOS/NP and MG63 osteosarcoma cells along with exposure to high-LET neutrons. The relationship between radiosensitivity and autophagy was assessed by plotting the cell surviving fractions against autophagy levels. Neutron treatment increased autophagy rates in irradiated KHOS/NP and MG63 cells; neutrons with high-LETs showed more effective inhibition than those with lower LET gamma-rays. To determine whether the unfolded protein response and Akt-mTOR pathways triggered autophagy, phosphorylated eIF2α and JNK levels, and phospho-Akt, phosphor-mTOR, and phospho-p70S6 levels were, respectively, investigated. High-LET neutron exposure inhibited Akt phosphorylation and increased Beclin 1 expression during the unfolded protein response, thereby enhancing autophagy. The therapeutic efficacy of high-LET neutron radiation was also assessed in vivo using an orthotopic mouse model. Neutron-irradiated mice showed reduced tumor growth without toxicity relative to gamma-ray-treated mice. The effect of high-LET neutron exposure on the expression of signaling proteins LC3, p-elF2a, and p-JNK was investigated by immunohistochemistry. Tumors in high-LET-neutron radiation-treated mice showed higher apoptosis rates, and neutron exposure significantly elevated LC3 expression, and increased p-elF2a and p-JNK expression levels. Overall, these results demonstrate that autophagy is important in radiosensitivity, cell survival, and cellular resistance against high-LET neutron radiation. This correlation between cellular radiosensitivity and autophagy may be used to predict radiosensitivity in osteosarcoma.
Collapse
Affiliation(s)
- Ju Yeon Oh
- Laboratory of Biochemistry, Division of Life Sciences, Korea University, Seongbuk-gu, Seoul 02841, Korea;
| | - Yeon-Joo Lee
- Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea;
| | - Sei Sai
- Department of Basic Medical Sciences for Radiation Damages, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263–8555, Japan;
| | - Tatsuya Ohno
- Gunma University Heavy Ion Medical Center, 3–39–22 Showa-machi, Maebashi 371–8511, Japan;
| | - Chang-Bae Kong
- Department of Orthopedic Surgery, Korea Institute of Radiological and Medical Sciences, Seoul 139–706, Korea;
| | - Sun Ha Lim
- Department of Biochemistry, School of Medicine, Daegu Catholic University, Duryugongwon-ro, Nam-gu, Daegu 42472, Korea;
| | - Eun Ho Kim
- Department of Biochemistry, School of Medicine, Daegu Catholic University, Duryugongwon-ro, Nam-gu, Daegu 42472, Korea;
- Correspondence: ; Tel.: +82-53-650-4480
| |
Collapse
|
4
|
Snyder M, Hammoud A, Bossenberger T, Spink R, Burmeister J. Intensity modulated neutron radiotherapy optimization by photon proxy. Med Phys 2012; 39:4992-8. [DOI: 10.1118/1.4737024] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
5
|
In vivo skin leptin modulation after 14 MeV neutron irradiation: a molecular and FT-IR spectroscopic study. Anal Bioanal Chem 2012; 404:1317-26. [DOI: 10.1007/s00216-012-6018-3] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2012] [Revised: 03/27/2012] [Accepted: 04/03/2012] [Indexed: 01/08/2023]
|
6
|
Fratini E, Licursi V, Artibani M, Kobos K, Colautti P, Negri R, Amendola R. Dose-dependent onset of regenerative program in neutron irradiated mouse skin. PLoS One 2011; 6:e19242. [PMID: 21556364 PMCID: PMC3083422 DOI: 10.1371/journal.pone.0019242] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2010] [Accepted: 03/29/2011] [Indexed: 02/07/2023] Open
Abstract
Background Tissue response to irradiation is not easily recapitulated by cell culture studies. The objective of this investigation was to characterize, the transcriptional response and the onset of regenerative processes in mouse skin irradiated with different doses of fast neutrons. Methodology/Principal Findings To monitor general response to irradiation and individual animal to animal variation, we performed gene and protein expression analysis with both pooled and individual mouse samples. A high-throughput gene expression analysis, by DNA oligonucleotide microarray was done with three months old C57Bl/6 mice irradiated with 0.2 and 1 Gy of mono-energetic 14 MeV neutron compared to sham irradiated controls. The results on 440 irradiation modulated genes, partially validated by quantitative real time RT-PCR, showed a dose-dependent up-regulation of a sub-class of keratin and keratin associated proteins, and members of the S100 family of Ca2+-binding proteins. Immunohistochemistry confirmed mRNA expression data enabled mapping of protein expression. Interestingly, proteins up-regulated in thickening epidermis: keratin 6 and S100A8 showed the most significant up-regulation and the least mouse-to-mouse variation following 0.2 Gy irradiation, in a concerted effort toward skin tissue regeneration. Conversely, mice irradiated at 1 Gy showed most evidence of apoptosis (Caspase-3 and TUNEL staining) and most 8-oxo-G accumulation at 24 h post-irradiation. Moreover, no cell proliferation accompanied 1 Gy exposure as shown by Ki67 immunohistochemistry. Conclusions/Significance The dose-dependent differential gene expression at the tissue level following in vivo exposure to neutron radiation is reminiscent of the onset of re-epithelialization and wound healing and depends on the proportion of cells carrying multiple chromosomal lesions in the entire tissue. Thus, this study presents in vivo evidence of a skin regenerative program exerted independently from DNA repair-associated pathways.
Collapse
Affiliation(s)
- Emiliano Fratini
- ENEA, Agenzia nazionale per le nuove tecnologie, l′energia e lo sviluppo economico sostenibile Roma, Italy
| | - Valerio Licursi
- Sapienza Università di Roma, Dipartimento di Biologia e Biotecnologie “Charles Darwin”, Roma, Italy
| | - Mara Artibani
- ENEA, Agenzia nazionale per le nuove tecnologie, l′energia e lo sviluppo economico sostenibile Roma, Italy
| | - Katarzyna Kobos
- ENEA, Agenzia nazionale per le nuove tecnologie, l′energia e lo sviluppo economico sostenibile Roma, Italy
| | | | - Rodolfo Negri
- Sapienza Università di Roma, Dipartimento di Biologia e Biotecnologie “Charles Darwin”, Roma, Italy
- Istituto Pasteur-Fondazione Cenci Bolognetti, Roma, Italy
| | - Roberto Amendola
- ENEA, Agenzia nazionale per le nuove tecnologie, l′energia e lo sviluppo economico sostenibile Roma, Italy
- * E-mail:
| |
Collapse
|
7
|
Spence AM, Muzi M, Swanson KR, O'Sullivan F, Rockhill JK, Rajendran JG, Adamsen TCH, Link JM, Swanson PE, Yagle KJ, Rostomily RC, Silbergeld DL, Krohn KA. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 2008; 14:2623-30. [PMID: 18451225 DOI: 10.1158/1078-0432.ccr-07-4995] [Citation(s) in RCA: 209] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
PURPOSE Hypoxia is associated with resistance to radiotherapy and chemotherapy and activates transcription factors that support cell survival and migration. We measured the volume of hypoxic tumor and the maximum level of hypoxia in glioblastoma multiforme before radiotherapy with [(18)F]fluoromisonidazole positron emission tomography to assess their impact on time to progression (TTP) or survival. EXPERIMENTAL DESIGN Twenty-two patients were studied before biopsy or between resection and starting radiotherapy. Each had a 20-minute emission scan 2 hours after i.v. injection of 7 mCi of [(18)F]fluoromisonidazole. Venous blood samples taken during imaging were used to create tissue to blood concentration (T/B) ratios. The volume of tumor with T/B values above 1.2 defined the hypoxic volume (HV). Maximum T/B values (T/B(max)) were determined from the pixel with the highest uptake. RESULTS Kaplan-Meier plots showed shorter TTP and survival in patients whose tumors contained HVs or tumor T/B(max) ratios greater than the median (P < or = 0.001). In univariate analyses, greater HV or tumor T/B(max) were associated with shorter TTP or survival (P < 0.002). Multivariate analyses for survival and TTP against the covariates HV (or T/B(max)), magnetic resonance imaging (MRI) T1Gd volume, age, and Karnovsky performance score reached significance only for HV (or T/B(max); P < 0.03). CONCLUSIONS The volume and intensity of hypoxia in glioblastoma multiforme before radiotherapy are strongly associated with poorer TTP and survival. This type of imaging could be integrated into new treatment strategies to target hypoxia more aggressively in glioblastoma multiforme and could be applied to assess the treatment outcomes.
Collapse
Affiliation(s)
- Alexander M Spence
- Department of Neurology, University of Washington, Seattle, Washington 98195, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Parvez T. Present trend in the primary treatment of aggressive malignant glioma: glioblastoma multiforme. Technol Cancer Res Treat 2008; 7:241-8. [PMID: 18473496 DOI: 10.1177/153303460800700310] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The standard treatment for glioblastoma multiforme is surgery, radiation, and chemotherapy. Yet this aggressive therapy has only a modest effect on survival with most patients surviving less than 1 year after diagnosis. This poor prognosis has lead scientists to seek alternative molecular approaches for the treatment of glioblastoma multiforme. Among these, gene therapy, vaccine therapy, and immunotherapy are all approaches that are currently being investigated. While these molecular approaches may not herald an immediate change in the prognosis of these aggressive tumors, combining them with existing approaches may bring some progress in the standard of care. This paper reviews current treatments and several newer therapies in preclinical and early clinical studies.
Collapse
Affiliation(s)
- Tariq Parvez
- Medical Director II Oncology, PRA International, Charlottesville, VA 22911, USA.
| |
Collapse
|